NDC 50419-393
VITRAKVI
Larotrectinib
VITRAKVI is a Oropharyngeal Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Bayer Healthcare Pharmaceuticals Inc.. The primary component is Larotrectinib.
| Product ID | 50419-393_257059c9-5fa8-4a5c-ae92-4462de9e8ec8 |
| NDC | 50419-393 |
| Product Type | Human Prescription Drug |
| Proprietary Name | VITRAKVI |
| Generic Name | Larotrectinib |
| Dosage Form | Solution, Concentrate |
| Route of Administration | OROPHARYNGEAL |
| Marketing Start Date | 2022-12-06 |
| Marketing Category | NDA / |
| Application Number | NDA211710 |
| Labeler Name | Bayer HealthCare Pharmaceuticals Inc. |
| Substance Name | LAROTRECTINIB |
| Active Ingredient Strength | 20 mg/mL |
| Pharm Classes | Kinase Inhibitor [EPC], Tropomyosin Receptor Kinases Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
Packaging
NDC 50419-393-03
2 BOTTLE in 1 CARTON (50419-393-03) > 50 mL in 1 BOTTLE (50419-393-02)
| Marketing Start Date | 2022-12-06 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
NDC Crossover Matching brand name "VITRAKVI" or generic name "Larotrectinib"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 50419-390 | VITRAKVI | LAROTRECTINIB |
| 50419-391 | VITRAKVI | LAROTRECTINIB |
| 50419-392 | VITRAKVI | LAROTRECTINIB |
| 50419-393 | VITRAKVI | LAROTRECTINIB |
| 71777-390 | VITRAKVI | LAROTRECTINIB |
| 71777-391 | VITRAKVI | LAROTRECTINIB |
| 71777-392 | VITRAKVI | LAROTRECTINIB |
Trademark Results [VITRAKVI]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 VITRAKVI 87819990 5584983 Live/Registered |
Bayer Aktiengesellschaft 2018-03-05 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.